Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MAB-22 vs Prolia in Postmenopausal Osteoporosis
NCT06504966Phase 3Withdrawn
- Sponsor
- Xentria
- Start
- Oct 2025
- Primary completion
- Oct 2027
- Modality
- Monoclonal Antibodies
01
Overview
A Phase 3 trial of INTP23 in osteoporosis, sponsored by Xentria. Planned start Oct 2025; status: withdrawn.
02
Drugs
INTP23
03
Conditions
osteoporosis
Beyond the preview
Go deeper on NCT06504966.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06504966.